Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0BEQQL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN110974975B C-01
|
|||||
| Synonyms |
C-01
Click to Show/Hide
|
|||||
| Organization |
Chengdu Bailidote Biological Pharmaceutical Co ltd; Sichuan Baili Pharmaceutical Co Ltd
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.21
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Coumpound7
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Coumpound7-Exatecan
|
|||||